Novartis Korea, KFDA mulls voluntary withdrawal of Zelmac
The U.S. Food and Drug Administration said on March 30 that Novartis had halted sales of tegaserod (Zelnorm), its agent for irritable bow...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
